226 related articles for article (PubMed ID: 22867945)
1. Targeting Jab1/CSN5 in nasopharyngeal carcinoma.
Pan Y; Claret FX
Cancer Lett; 2012 Dec; 326(2):155-60. PubMed ID: 22867945
[TBL] [Abstract][Full Text] [Related]
2. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
4. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5.
Wang S; Pan Y; Zhang R; Xu T; Wu W; Zhang R; Wang C; Huang H; Calin CA; Yang H; Claret FX
Oncogene; 2016 Nov; 35(47):6096-6108. PubMed ID: 27157611
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.
Pan Y; Yang H; Claret FX
Cancer Biol Ther; 2014 Mar; 15(3):256-62. PubMed ID: 24495954
[TBL] [Abstract][Full Text] [Related]
6. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma.
Pan Y; Wang M; Bu X; Zuo Y; Wang S; Wang D; Liu Q; Su B; Xu T; Wang C; Claret FX; Yang H
BMC Cancer; 2013 Jul; 13():323. PubMed ID: 23815987
[TBL] [Abstract][Full Text] [Related]
7. The emerging roles of Jab1/CSN5 in cancer.
Wang L; Zheng JN; Pei DS
Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
[TBL] [Abstract][Full Text] [Related]
8. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma.
Pan Y; Zhang Q; Tian L; Wang X; Fan X; Zhang H; Claret FX; Yang H
Cancer Res; 2012 Apr; 72(7):1890-900. PubMed ID: 22350412
[TBL] [Abstract][Full Text] [Related]
9. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.
Xu T; Su B; Wang C; Wang S; Huang H; Pan Y; Wang D; Wei W; Claret FX; Yang H
Oncol Rep; 2015 Mar; 33(3):1418-26. PubMed ID: 25607111
[TBL] [Abstract][Full Text] [Related]
12. CSN5/Jab1 facilitates non-small cell lung cancer cell growth through stabilizing survivin.
Li J; Li Y; Wang B; Ma Y; Chen P
Biochem Biophys Res Commun; 2018 Jun; 500(2):132-138. PubMed ID: 29596838
[TBL] [Abstract][Full Text] [Related]
13. CSN5/Jab1 controls multiple events in the mammalian cell cycle.
Yoshida A; Yoneda-Kato N; Panattoni M; Pardi R; Kato JY
FEBS Lett; 2010 Nov; 584(22):4545-52. PubMed ID: 20974137
[TBL] [Abstract][Full Text] [Related]
14. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
[TBL] [Abstract][Full Text] [Related]
15. JAB1/CSN5 and the COP9 signalosome. A complex situation.
Chamovitz DA; Segal D
EMBO Rep; 2001 Feb; 2(2):96-101. PubMed ID: 11258719
[TBL] [Abstract][Full Text] [Related]
16. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
[TBL] [Abstract][Full Text] [Related]
17. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
[TBL] [Abstract][Full Text] [Related]
18. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
19. JAB1/CSN5: a new player in cell cycle control and cancer.
Shackleford TJ; Claret FX
Cell Div; 2010 Oct; 5():26. PubMed ID: 20955608
[TBL] [Abstract][Full Text] [Related]
20. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
